Meeting Healthcare in South Africa: First Impressions

Meeting Healthcare in South Africa: First Impressions By Julie Hugunin, Biology, 2017 Just as we begin to poke the woman with a needle the power goes out — again. “Are you sure we shouldn’t be worried?” my unsteady voice asks, clearly naïve and inexperienced to life in a South African township. “Yes, electricity is always a problem

Meeting Healthcare in South Africa: First Impressions Read More »

Regulation and Science: Biosimilars Waiting to Debut in the US

Regulation and Science: Biosimilars Waiting to Debut in the US Editorial by Josh Sternberg, Editor-in-Chief at Northeastern Univeristy Political Review The pharmaceutical industry is experiencing tectonic shifts, with widespread effects on the traditional business models of pharmaceutical companies. Drying pipelines, pricing pressures, health care reform, and rising costs of research and development are forcing pharmaceutical companies

Regulation and Science: Biosimilars Waiting to Debut in the US Read More »

Should GMOs be labeled?

Should GMOs be labeled? By Gwen Schanker Whether organisms should be genetically modified has been a subject of debate since the 1970s, when scientists Stanley Cohen and Herbert Boyer created the first recombinant DNA organism and transgenic plants emerged as the newest breakthrough in biotechnology. Genetic modification of crops allows for greater yields at a lower

Should GMOs be labeled? Read More »

STAP in the Name of Love — The Dangers of Scientific Overreach

STAP in the Name of Love — The Dangers of Scientific Overreach By Gwen Schanker, Journalism and Biology, 2017 Science is constantly evolving. Every day, new phenomena, techniques and ideas are discovered and explored. Scientists live and work in a continually shifting environment, where with the right amount of resources, research and testing, they can investigate any

STAP in the Name of Love — The Dangers of Scientific Overreach Read More »